Evidence map›Paper›PMID 37684276›Full record

Observational studyScientific reports2023

Leveraging the COVID-19 pandemic as a natural experiment to assess changes in antibiotic use and antibiotic-resistant E. coli carriage in semi-rural Ecuador.

Heather K Amato, Fernanda Loayza, Liseth Salinas, Diana Paredes, Daniela García, Soledad Sarzosa, Carlos Saraiva-Garcia, Timothy J Johnson, Amy J Pickering, Lee W Riley and 2 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Shifts inMicrobiology spectrum · 2025
    Article
  3. Article
  4. Article
  5. Human carriage of ESBL/pAmpC-producingMicrobiology spectrum · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Heather K AmatoEnvironmental Health Sciences Division, School of Public Health, University of California, Berkeley, CA, USA. heather_amato@berkeley.edu.
Fernanda LoayzaInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Pichincha, Ecuador.
Liseth SalinasInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Pichincha, Ecuador.
Diana ParedesInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Pichincha, Ecuador.
Daniela GarcíaInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Pichincha, Ecuador.
Soledad SarzosaInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Pichincha, Ecuador.
Carlos Saraiva-GarciaInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Pichincha, Ecuador.
Timothy J JohnsonDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN, USA.
Amy J PickeringDepartment of Civil and Environmental Engineering, University of California, Berkeley, CA, USA.
Lee W RileyDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, 94720, USA.
Gabriel TruebaInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Pichincha, Ecuador.
Jay P GrahamEnvironmental Health Sciences Division, School of Public Health, University of California, Berkeley, CA, USA.
Universidad San Francisco de Quito · ECUniversity of California, Berkeley · USChan Zuckerberg Initiative (United States) · USUniversity of Minnesota · US

Funding

Antimicrobial Resistance Transmission Associated with Small-Scale Food-Animal Production in Peri-Urban Communities of Quito, EcuadorR01AI135118 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI GRAHAM, JAY PAUL · 2018 to 2021
$2.0M
NIAID NIH HHS R01 AI135118
6 · The paper itself

Abstract

The coronavirus 2019 (COVID-19) pandemic has had significant impacts on health systems, population dynamics, public health awareness, and antibiotic stewardship, which could affect antibiotic resistant bacteria (ARB) emergence and transmission. In this study, we aimed to compare knowledge, attitudes, and practices (KAP) of antibiotic use and ARB carriage in Ecuadorian communities before versus after the COVID-19 pandemic began. We leveraged data collected for a repeated measures observational study of third-generation cephalosporin-resistant E. coli (3GCR-EC) carriage among children in semi-rural communities in Quito, Ecuador between July 2018 and September 2021. We included 241 households that participated in surveys and child stool sample collection in 2019, before the pandemic, and in 2021, after the pandemic began. We estimated adjusted Prevalence Ratios (aPR) and 95% Confidence Intervals (CI) using logistic and Poisson regression models. Child antibiotic use in the last 3 months declined from 17% pre-pandemic to 5% in 2021 (aPR: 0.30; 95% CI 0.15, 0.61) and 3GCR-EC carriage among children declined from 40 to 23% (aPR: 0.48; 95% CI 0.32, 0.73). Multi-drug resistance declined from 86 to 70% (aPR: 0.32; 95% CI 0.13; 0.79), the average number of antibiotic resistance genes (ARGs) per 3GCR-EC isolate declined from 9.9 to 7.8 (aPR of 0.79; 95% CI 0.65, 0.96), and the diversity of ARGs was lower in 2021. In the context of Ecuador, where COVID-19 prevention and control measures were strictly enforced after its major cities experienced some of the world's the highest mortality rates from SARS-CoV-2 infections, antibiotic use and ARB carriage declined in semi-rural communities of Quito from 2019 to 2021.

Indexed as

COVID-19Escherichia coliAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnti-Bacterial AgentsChildEcuadorHumansPandemicsRural PopulationSARS-CoV-2Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnti-Bacterial Agents

Identifiers

PMID37684276
PMCPMC10491794
OpenAlexW4386547606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.